Biologic Patent Protection: When Biosimilars Can Enter the U.S. Market
Biosimilars in the U.S. face a 12-year exclusivity barrier under the BPCIA, delaying affordable access to life-saving biologics like Humira. Patent thickets, complex manufacturing, and litigation slow competition - costing patients billions.
